Switching from Oral RISPERDAL®

Dose Information

Graph Information

^ Back to Top

Switching from Oral RISPERDAL®

Consistent with the RISPERDAL® Prescribing Information:

  • RISPERDAL® is an atypical antipsychotic indicated for the treatment of schizophrenia.
  • RISPERDAL® can be administered once or twice daily. The initial dose of RISPERDAL® for treatment of schizophrenia in adults is 2 mg/day. May increase the dose at intervals of 24 hours or greater, in increments of 1 to 2 mg per day, as tolerated, to a recommended dose of 4 to 8 mg per day. Doses above 6 per day were not demonstrated to be more efficacious than lower doses, were associated with more extrapyramidal symptoms and other adverse effects, and are generally not recommended.

Consistent with the INVEGA SUSTENNA® Prescribing Information:

  • There are no systematically collected data to specifically address switching patients with schizophrenia or schizoaffective disorder from other antipsychotics to INVEGA SUSTENNA®, or concerning concomitant administration with other antipsychotics.
  • For patients who have never taken oral paliperidone or oral or injectable risperidone, tolerability should be established with oral paliperidone or oral risperidone prior to initiating treatment with INVEGA SUSTENNA®.
  • Previous oral antipsychotics can be gradually discontinued at the time of initiation of treatment with INVEGA SUSTENNA®.
  • All patients transitioning from oral antipsychotics must follow the recommended initiation dosing of 234 mg (day 1), 156 mg (day 8) both administered in the deltoid muscle.)
  • The initiation regimen (234 mg followed by 156 mg one week later both in the deltoid muscle) rapidly attains steady-state paliperidone concentrations with no need for oral antipsychotic supplementation.
  • The recommended maintenance dose of INVEGA SUSTENNA® for treatment of schizophrenia is 117 mg. Some patients may benefit from lower or higher maintenance doses within the additional available strengths (39 mg, 78 mg, 156 mg, and 234 mg).
  • Patients stabilized on risperidone tablets can attain similar steady-state exposure with INVEGA SUSTENNA® as depicted in Table. The INVEGA SUSTENNA® Prescribing Information does not specifically address conversion of RISPERDAL® tablets to INVEGA SUSTENNA®. This information is based on pharmacokinetic (PK) modeling performed to compare steady-state exposure during maintenance treatment between RISPERDAL® tablets and INVEGA SUSTENNA® (after both the 234 mg/156 mg deltoid starting doses).*
Table: Doses of RISPERDAL® and INVEGA SUSTENNA® Needed to Attain Similar Steady-State Palliperidone Exposure During Maintenance Treatment.*
Formulation RISPERDAL® Tablet INVEGA SUSTENNA® Injection
Dosing Frequency Total Daily Dose Every 4 Weeks
Dose (mg) 6 234
4 156
3 117
2 78
1 39

*Russu A, Sliwa JK, Ravestijn P, et al. Maintenance dose conversion between oral risperidone and paliperidone palmitate 1 month: Practical guidance based on pharmacokinetic simulations. Int J Clin Pract. 2018;e13089.

  • Administration: Each injection must be administered only by a healthcare professional. INVEGA SUSTENNA® is intended for intramuscular use only. Do not administer by any other route. Avoid inadvertent injection into a blood vessel.

INVEGA SUSTENNA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf]

RISPERDAL® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RISPERDAL-pi.pdf]

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:


  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants


  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

Please Confirm


Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel